Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 39 - Medicinal preparations containing antigens or antibodies
Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248)
03/2014
03/04/2014US8663655 Method for transforming a bacterium belonging to the Streptococcus genus by natural competence
03/04/2014US8663654 Polysaccharide vaccine for staphylococcal infections
03/04/2014US8663653 Efficient cell culture system for hepatitis C virus genotype 2B
03/04/2014US8663652 Regeneration of endogenous myocardial tissue
03/04/2014US8663651 T-140 peptide analogs having CXCR4 super-agonist activity for immunomodulation
03/04/2014US8663650 Methods and compositions comprising supramolecular constructs
03/04/2014US8663649 Diagnosis and treatment of Trypanosoma cruzi infection and Chagas disease
03/04/2014US8663648 Agents for treatment of HCV and methods of use
03/04/2014US8663647 Epitope peptides derived from vascular endothelial growth factor receptor 1 and vaccines containing these peptides
03/04/2014US8663646 P53 peptide vaccine
03/04/2014US8663645 Use of native peptides and their optimized derivatives for vaccination
03/04/2014US8663644 Augmentation of titer for vaccination in animals
03/04/2014US8663643 Combinations of an anti-HER2 antibody-drug conjugate and chemotherapeutic agents, and methods of use
03/04/2014US8663642 Anti-CD70 antibody-drug conjugates and their use for the treatment and prevention of cancer and immune disorders
03/04/2014US8663641 Anti-PSGL-1 antibodies
03/04/2014US8663640 Methods using recombinant anti-epidermal growth factor receptor antibody compositions
03/04/2014US8663639 Formulations for treating ocular diseases and conditions
03/04/2014US8663638 Intraoperative trifunctional antibody application for prophylaxis of intraperitoneal tumor cell dissemination
03/04/2014US8663637 Methods and compositions for modulation of Olfml3 mediated angiogenesis
03/04/2014US8663636 Method of treating a malignant tumor by administering antibodies directed to DLL4
03/04/2014US8663635 N-cadherin: target for cancer diagnosis and therapy
03/04/2014US8663634 Methods for the treatment of autoimmune disorders using immunosuppressive monoclonal antibodies with reduced toxicity
03/04/2014US8663622 Recombinant vaccine viruses expressing IL-15 and methods using the same
03/04/2014CA2551644C Recombinant nucleic acid molecules encoding fusion proteins comprising antigens and bacterial secretory signal polypeptides, expression cassettes, and bacteria, and methods of usethereof
03/04/2014CA2533918C Use of adcc-optimized antibodies for treating weak patients
02/2014
02/27/2014WO2014032021A1 Antibody drug conjugates (adc) that bind to 158p1d7 proteins
02/27/2014WO2014031883A1 Neurotherapeutic nanoparticle compositions and devices
02/27/2014WO2014031822A1 Anti-poly-n-acetyl glucosamine (pnag) monoclonal antibody and uses thereof for the prevention or treatment of pnag expressing bacterial infection
02/27/2014WO2014031727A1 Ferritin-based tumor targeting agent, and imaging and treatment methods
02/27/2014WO2014031718A1 Stable formulations of antibodies to tslp
02/27/2014WO2014031712A1 HUMAN ANTIBODIES TO GFRα3 AND METHODS OF USE THEREOF
02/27/2014WO2014031697A2 COMPOSITIONS AND METHODS RELATED TO DISEASES ASSOCIATED WITH DEPOSITS OF AMYLOID, TAU, AND α-SYNUCLEIN
02/27/2014WO2014031687A1 Method and compositions for cellular immunotherapy
02/27/2014WO2014031610A1 Methods for treating or preventing asthma by administering an il-4r antagonist
02/27/2014WO2014031595A1 Haptens of paliperidone
02/27/2014WO2014031594A2 Modulating voltage-operated calcium channels on immune cells
02/27/2014WO2014031429A2 Liposome formulations
02/27/2014WO2014030750A1 MOUSE FcγRII-SPECIFIC Fc ANTIBODY
02/27/2014WO2014030728A1 Fcγriib-specific fc region variant
02/27/2014WO2014030137A1 Vaccine strain marked with the plague virus of small ruminants, and preparation method thereof
02/27/2014WO2014030003A1 Neisseria meningitidis fhbp variant and its use for vaccination
02/27/2014WO2014029702A1 Liquid stable virus vaccines
02/27/2014WO2014011465A3 Aptamer-targeted antigen delivery
02/27/2014WO2014008206A3 DIAGNOSTIC AND THERAPEUTIC POTENTIAL OF HLA-E MONOSPECIFIC MONOCLONAL IgG ANTIBODIES DIRECTED AGAINST TUMOR CELL SURFACE AND SOLUBLE HLA-E
02/27/2014WO2014002035A3 A human monoclonal antibody against the vp1 protein of jc virus
02/27/2014WO2013192144A3 Rift valley fever virus replicon particles
02/27/2014WO2013188870A3 IgA CD4i ANTIBODIES AND METHODS OF TREATMENT USING SAME
02/27/2014WO2013179299A3 An anti-allergic medicament
02/27/2014WO2013166011A3 Binding proteins having tethered light chains
02/27/2014WO2013013302A8 Synthetic lethality and the treatment of cancer
02/27/2014WO2012138774A3 Methods of improving vaccine immunogenicity
02/27/2014US20140058063 Vitamin receptor binding drug delivery conjugates
02/27/2014US20140057832 Use of relaxin to increase arterial compliance
02/27/2014US20140056972 Anti-dclk1 monoclonal antibodies and methods of production and use thereof
02/27/2014US20140056958 Apparatus, system, and method for creating biologically protected/enhanced spaces in vivo
02/27/2014US20140056944 Isolation of lymphocytes and delivery to splenectomy patients
02/27/2014US20140056943 Immuno-stimulant combination for prophylaxis and treatment of hepatitis c
02/27/2014US20140056942 Liquid stable virus vaccines
02/27/2014US20140056941 Antigenic formulation
02/27/2014US20140056940 Novel adjuvant compositions
02/27/2014US20140056939 Enhancing the t-cell stimulatory capacity of human antigen presenting cells in vitro and in vivo and its use in vaccination
02/27/2014US20140056936 Compositions and methods using recombinant mhc molecules for the treatment of stroke
02/27/2014US20140056933 Immunostimulatory nucleic acid packaged particles for the treatment of hypersensitivity
02/27/2014US20140056930 Using pomegranate extracts for increasing prostate specific antigen doubling time
02/27/2014US20140056928 Novel compounds
02/27/2014US20140056923 Method of treating hypertension disorder and a pharmaceutical agent
02/27/2014US20140056922 Methods for using extracellular adenosine inhibitors and adenosine receptor inhibitors to enhance immune response and inflammation
02/27/2014US20140056921 Hepatocyte Growth Factor Receptor Antagonists and Uses Thereof
02/27/2014US20140056920 Methods for treating or preventing asthma by administering an il-4r antagonist
02/27/2014US20140056919 Methods and compositions for treating inflammatory conditions
02/27/2014US20140056917 FTY720 Increases CD74 Expression and Sensitizes Cancer Cells to Anti-CD74 Antibody-Mediated Cell Death
02/27/2014US20140056914 Human cytomegalovirus neutralising antibodies and use thereof
02/27/2014US20140056912 Methods of treating squamous cell carcinoma
02/27/2014US20140056911 Breast Endothelial Cell Expression Patterns
02/27/2014US20140056910 Therapeutic agent for cancer having reduced sensitivity to molecular target drug and pharmaceutical composition for enhancing sensitivity to molecular target drug
02/27/2014US20140056909 Treating cancer
02/27/2014US20140056905 Anti-kit antibodies and uses thereof
02/27/2014US20140056903 Human antibodies to gfr alpha 3 and methods of use thereof
02/27/2014US20140056902 Pharmaceutical agent comprising anti-bmp9 antibody as active ingredient for treatment of anemia such as renal anemia and cancer anemia
02/27/2014US20140056898 Combination therapies comprising anti-erbb3 agents
02/27/2014US20140056896 Anti-cd19 antibodies and uses in b cell disorders
02/27/2014US20140056894 Rspondins as modulators of angiogenesis and vasculogenesis
02/27/2014US20140056892 VISTA-Ig for Treatment of Autoimmune, Allergic and Inflammatory Disorders
02/27/2014US20140056891 Treatment of cancer with elevated dosages of soluble fgfr1 fusion proteins
02/27/2014US20140056890 Binding Agents That Modulate the Hippo Pathway and Uses Thereof
02/27/2014US20140056889 Compositions and method for treating autoimmune diseases
02/27/2014US20140056888 High concentration antibody formulations
02/27/2014US20140056887 Combination therapies for b-cell lymphomas comprising administration of anti-cd20 antibody
02/27/2014US20140056886 Humanized Anti-IL-20 Antibody And Uses Thereof
02/27/2014US20140056885 Subcutaneously administered anti-il-6 receptor antibody
02/27/2014US20140056884 Subcutaneously administered anti-il-6 receptor antibody
02/27/2014US20140056883 Subcutaneously administered anti-il-6 receptor antibody
02/27/2014US20140056882 Treatment of pulmonary disease conditions
02/27/2014US20140056877 Stabilized Liquid Anti-RSV Antibody Formulations
02/27/2014US20140056876 Method to identify a pateint with an increased likelihood of responding to an anti-cancer therapy
02/27/2014US20140056875 Method to identify a pateint with an increased likelihood of responding to an anti-cancer therapy
02/27/2014US20140056874 Method to identify a pateint with an increased likelihood of responding to an anti-cancer therapy
02/27/2014US20140056873 Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation
02/27/2014US20140056872 Antagonists of neuropilin receptor function and use thereof
02/27/2014US20140056845 Method for Generating Potent Dendritic Cells
1 ... 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 ... 1823